Colgate-Palmolive Amends 8-K Filing

TL;DR

Colgate-Palmolive just amended its October 25th financial report - check the details.

AI Summary

Colgate-Palmolive Company filed an 8-K/A on January 24, 2025, to amend its previous filing. The amendment pertains to the results of operations and financial condition as of October 25, 2024, and includes financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This amendment indicates a formal update or correction to Colgate-Palmolive's previously reported financial information, ensuring accuracy for investors and regulatory bodies.

Risk Assessment

Risk Level: low — This filing is an amendment to a previous report and does not introduce new material risks or significant financial changes.

Key Players & Entities

• COLGATE PALMOLIVE CO (company) — Registrant
• October 25, 2024 (date) — Date of earliest event reported
• January 24, 2025 (date) — Filing date
• 300 Park Avenue, New York, NY 10022 (address) — Principal Executive Office Address

FAQ

Key Financial Figures

• $1.00 — ge on which registered Common Stock, $1.00 par value CL New York Stock Exchange

Filing Documents

• cl-20241025.htm (8-K/A) — 47KB
• q32024pressreleasetables.htm (EX-99.1) — 720KB
• recastsegmentinformation.htm (EX-99.2) — 178KB
• logoheaderforir.jpg (GRAPHIC) — 49KB
• 0000021665-25-000002.txt ( ) — 1226KB
• cl-20241025.xsd (EX-101.SCH) — 3KB
• cl-20241025_def.xml (EX-101.DEF) — 9KB
• cl-20241025_lab.xml (EX-101.LAB) — 30KB
• cl-20241025_pre.xml (EX-101.PRE) — 17KB
• cl-20241025_htm.xml (XML) — 6KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On October 25, 2024, Colgate-Palmolive Company (the "Company") issued a press release announcing its earnings for the quarter ended September 30, 2024. This press release is attached as Exhibit 99.1 and is incorporated herein by reference. The information in Item 2.02 of this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

01. Other Events

Item 8.01. Other Events. In connection with management changes, the Company realigned the reporting structure of its skin health business effective July 1, 2024. Accordingly, commencing with the Company's financial reporting for the quarter ended September 30, 2024, the results of the skin health business previously reported within the Europe reportable operating segment are reported with the other skin health businesses in the North America reportable operating segment, with no impact on the Company's consolidated results of operations or financial position. For information purposes and to provide investors with historical information on a basis consistent with its new reporting structure, the Company has recast its historical geographic segment information to conform to the new reporting structure. Attached as Exhibit 99.2 and incorporated by reference in this Item 8.01 are schedules containing segment information by operating segment for the years ended December 31, 2023, 2022 and 2021, the three and six months ended June 30, 2024 and 2023, the three months ended March 31, 2024 and 2023 and the three months ended December 31, 2023. As noted above, the segment change and supplemental disclosures discussed above have no impact on the Company's historical consolidated financial position, results of operations or cash flows. The recast financial information contained in Exhibit 99.2 does not represent a restatement of previously issued financial statements. The information in this Item 8.01, including Exhibit 99.2, should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are filed with this document: Exhibit Number Description 99.1 Press release, dated October 25, 2024, issued by Colgate-Palmolive Company 99.2 Recast segment information of Colgate-Palmolive Company 104 Cover Page Interactive Data File (embedded within the Inline eXtensible Business Reporting Language (Inline XBRL) document) 2 EXHIBIT INDEX Exhibit Number Description 99.1 Press release, dated October 25, 2024, issued by Colgate-Palmolive Company 99.2 Recast segment information of Colgate-Palmolive Company 104 Cover Page Interactive Data File (embedded within the Inline eXtensible Business Reporting Language (Inline XBRL) document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. > COLGATE-PALMOLIVE COMPANY Date: January 24, 2025 By: /s/ Gregory O. Malcolm Name: Gregory O. Malcolm Title: Executive Vice President, Controller 4

View Full Filing

View this 8-K/A filing on SEC EDGAR